ALS Invest 1 B.V. - Jan 6, 2022 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role: 10%+ Owner
Signature: /s/ Felix-Andre von Coerper
Stock symbol: AMLX
Transactions as of: Jan 6, 2022
Transactions value $: $0
Form type: 4
Date filed: 5/5/2022, 04:46 PM
Next filing: Jul 8, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AMLX	Common Stock	Conversion of derivative security		+1.13M			1.13M	Jan 11, 2022	Direct	F1, F2
transaction	AMLX	Common Stock	Conversion of derivative security		+4.83M	+427.36%		5.96M	Jan 11, 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AMLX	Series A Preferred Stock	Conversion of derivative security	$0	-1.13M	-100%	$0.00^*	0	Jan 11, 2022	Common Stock	1.13M		Direct	F1, F2
transaction	AMLX	Series B Preferred Stock	Conversion of derivative security	$0	-4.83M	-100%	$0.00^*	0	Jan 11, 2022	Common Stock	4.83M		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Upon the closing of the Issuer's initial public offering, all shares of Series A and Series B preferred stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date.
F2	The Reporting Person is managed by SUNU Ventures BV. Felix-Andre von Coerper is the sole corporate director of SUNU Ventures BV and has voting and dispositive power with respect to the securities held by the Reporting Person.